• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Senti Biosciences, Inc. - Common Stock (NQ: SNTI )

    2.710 UNCHANGED
    Streaming Delayed Price Updated: 3:59 PM EDT, Aug 29, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 0
    Open 2.710
    Bid (Size) 2.580 (1)
    Ask (Size) 3.000 (8)
    Prev. Close 2.710
    Today's Range 2.710 - 2.710
    52wk Range 1.520 - 8.479
    Shares Outstanding 2,752,774
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    SNTI Stock Earnings: Senti Biosciences Reported Results for Q2 2024
    Senti Biosciences just reported results for the second quarter of 2024. 
    Via InvestorPlace
    Senti Bio Announces Reverse Stock Split
    Shares expected to begin trading on split-adjusted basis on July 18, 2024 
    From Senti Biosciences, Inc.
    Via GlobeNewswire

    Performance

    YTD
    -59.00%
    -59.00%
    1 Month
    +15.81%
    +15.81%
    3 Month
    -13.42%
    -13.42%
    6 Month
    -36.98%
    -36.98%
    1 Year
    -58.31%
    -58.31%

    More News

    Read More
    12 Health Care Stocks Moving In Thursday's Pre-Market Session
    Via Benzinga
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
    Via InvestorPlace
    SNTI Stock Earnings: Senti Biosciences Reported Results for Q1 2024
    Via InvestorPlace
    Complete Solaria, Senti, and POET: 3 High Volume Penny Stocks
    Via MarketBeat
    Senti Biosciences (SNTI) Stock Is Up Over 100%: What's Happening?
    Via Benzinga
    Senti Bio Awarded California Institute for Regenerative Medicines (CIRM) Grant for Clinical Development of Logic Gated CAR-NK Cell Therapy
    From Senti Biosciences, Inc.
    Via GlobeNewswire
    Why Is Beyond Air (XAIR) Stock Down 22% Today?
    Via InvestorPlace
    Why Is Faraday Future (FFIE) Stock Down 27% Today?
    Via InvestorPlace
    Why Is Senti Biosciences (SNTI) Stock Up 32% Today?
    Via InvestorPlace
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
    Via InvestorPlace
    12 Health Care Stocks Moving In Friday's After-Market Session
    Via Benzinga
    Senti Bio Announces First Patient Dosed in Phase 1 Clinical Trial of SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia
    From Senti Biosciences, Inc.
    Via GlobeNewswire
    Senti Bio Announces First Quarter 2024 Results and Reviews Recent Corporate Highlights
    From Senti Biosciences, Inc.
    Via GlobeNewswire
    Senti Bio Announces Publication of SENTI-202 Preclinical Data Demonstrating Potential of Logic-Gated CAR-NK Cell Therapy for the Treatment of Acute Myeloid Leukemia (AML)
    From Senti Biosciences, Inc.
    Via GlobeNewswire
    SNTI Stock Earnings: Senti Biosciences Misses EPS for Q4 2023
    Via InvestorPlace
    Senti Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Reviews Recent Highlights
    From Senti Biosciences, Inc.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Tuesday's After-Market Session
    Via Benzinga
    12 Health Care Stocks Moving In Monday's Pre-Market Session
    Via Benzinga
    Senti Bio Announces Strategic Steps to Prioritize Investment in Lead Clinical Program
    From Senti Biosciences, Inc.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Monday's Pre-Market Session
    Via Benzinga
    Why Is Blood Cancer Focused Senti Biosciences Stock Trading Higher Today?
    Via Benzinga
    Exposures Product Safety
    12 Health Care Stocks Moving In Friday's Pre-Market Session
    Via Benzinga
    Senti Bio Announces FDA Clearance of IND Application for SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia
    From Senti Biosciences, Inc.
    Via GlobeNewswire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.